Press Releases

Date Title and Summary View
Toggle Summary Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)
- Bone, Reproductive, and Urologic Drugs Advisory Committee Votes Unanimously in Favor of Unified IC/BPS Population for Clinical Trials - SILVER SPRING, Md. , Dec. 07, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company
View HTML
Toggle Summary Aquinox to Participate in 29th Annual Piper Jaffray Healthcare Conference
VANCOUVER, British Columbia , Nov. 22, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main
View HTML
Toggle Summary Aquinox Pharmaceuticals Announces Third Quarter 2017 Financial Results
VANCOUVER, British Columbia , Nov. 08, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today reported financial results
View HTML
Toggle Summary Aquinox to Present at 2017 Cantor Fitzgerald Global Healthcare Conference
VANCOUVER, British Columbia , Sept. 18, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main
View HTML
Toggle Summary Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome
- Meeting to be Held December 7, 2017 - VANCOUVER, British Columbia , Aug. 28, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and
View HTML
Toggle Summary Aquinox Pharmaceuticals Announces Second Quarter 2017 Financial Results
- Enrollment in LEADERSHIP 301 with Rosiptor in IC/BPS Passes 50% - - Selection of CP/CPPS as Second Clinical Indication - VANCOUVER, British Columbia , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering
View HTML
Toggle Summary Aquinox to Present at Canaccord Genuity 37th Annual Growth Conference
VANCOUVER, British Columbia , Aug. 02, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main
View HTML
Toggle Summary Aquinox Pharmaceuticals to Announce Second Quarter 2017 Financial Results
Conference call Tuesday August 8, 2016 at 8:30 AM ET
View HTML
Toggle Summary Aquinox to Present at Jefferies 2017 Global Healthcare Conference
VANCOUVER, British Columbia , June 01, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main
View HTML
Toggle Summary Aquinox Pharmaceuticals Announces First Quarter 2017 Financial Results
VANCOUVER, British Columbia , May 09, 2017 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, today provided a corporate update
View HTML